Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00293280 · ClinicalTrials.gov registry record · Phase 2

Lomustine in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

A Phase 2 study of Lung Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Completed
Registry status
Phase 2
Development phase
42
Enrollment target
1
Study location

NCT00293280 is a Phase 2 study of Lung Cancer that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 42 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00293280, a Phase 2 study of Lung Cancer, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

COMPLETED
Registry status
Phase 2
Development phase
42 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Drugs used in chemotherapy, such as lomustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well lomustine works in treating patients with stage III or stage IV non-small cell lung cancer.

Conditions Studied

Interventions

  • DRUG lomustine

Study Locations (1)

Maryland

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2005-07
Phase Phase 2

What the Registry Record Tells You About NCT00293280

The ClinicalTrials.gov registry entry for NCT00293280 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which lomustine is the first listed.

NCT00293280 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT00293280 about?

NCT00293280 is a clinical study titled "Lomustine in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy, such as lomustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well lomustine works in treating patients with stage III or stage IV non-sm...

What is the current status of trial NCT00293280?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2005-07.

What conditions does trial NCT00293280 study?

This clinical trial studies the following conditions: Lung Cancer.

What interventions are being tested in trial NCT00293280?

The interventions under investigation include: lomustine (DRUG).

Who is sponsoring clinical trial NCT00293280?

This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00293280 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.